Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Veradigm Inc.
  6. News
  7. Summary
    MDRX   US01988P1084

VERADIGM INC.

(MDRX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
17.00 USD   -1.73%
02/01Jopari Solutions and Veradigm Collaborate to Provide Electronic Claim & Attachment Solutions for Veradigm Payerpath™ Customers
CI
02/01Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17
MT
01/31Veradigm Network EHR Data is Now Available in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) Format
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating

11/18/2022 | 10:53am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about VERADIGM INC.
02/01Jopari Solutions and Veradigm Collaborate to Provide Electronic Claim & Attachment Solu..
CI
02/01Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $..
MT
01/31Veradigm Network EHR Data is Now Available in the Observational Medical Outcomes Partne..
AQ
01/30Veradigm® Network EHR Data is Now Available in the Observational Medical Outcomes Partn..
BU
01/11Transcript : Veradigm Inc. Presents at 41st Annual J.P. Morgan Healthcare Con..
CI
01/11Veradigm Approves Share Buyback Plan of Up to $250 Million, Provides Fiscal 2023 Guidan..
MT
01/11Veradigm Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/11Tranche Update on Veradigm Inc.'s Equity Buyback Plan announced on January 24, 2022.
CI
01/11Veradigm Inc. announces an Equity Buyback for $250 million worth of its shares.
CI
01/11Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fisc..
BU
More news
Analyst Recommendations on VERADIGM INC.
More recommendations
Financials (USD)
Sales 2022 615 M - -
Net income 2022 1,05 M - -
Net cash 2022 376 M - -
P/E ratio 2022 -425x
Yield 2022 -
Capitalization 1 857 M 1 857 M -
EV / Sales 2022 2,41x
EV / Sales 2023 2,32x
Nbr of Employees 8 000
Free-Float 38,1%
Chart VERADIGM INC.
Duration : Period :
Veradigm Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERADIGM INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 17,00 $
Average target price 22,07 $
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Richard J. Poulton Chief Executive Officer & Director
Thomas Langan President
Leah Jones Vice President-Finance & Sales Support
Joseph R. Rostock Chief Technology Officer & SVP-Product Engineering
Tejal Vakharia Chief Compliance Counsel & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
VERADIGM INC.-1.93%1 890
VEEVA SYSTEMS INC.10.52%27 767
PRO MEDICUS LIMITED24.21%4 992
EVOLENT HEALTH, INC.13.82%3 185
SECTRA AB (PUBL)8.82%2 969
OMNICELL, INC.13.70%2 560